| Abstrakt: |
Introduction: The COVID-19 pandemic, a disease caused by the new coronavirus (SARS-CoV-2), predominantly affects the upper airways, most of them mild and self-limiting. However, with potentially fatal consequences, such as respiratory failure and thromboembolic events. Although limited, there are also studies reporting hearing loss and vestibulocochlear implications in some patients. Objectives: Present alternative treatments for hearing loss associated with COVID-19 from a case report. Resumed report: C.C, 38 years old, white, previously healthy. Gastrointestinal complaints, vertigo, tinnitus and hearing loss on the left, with sudden onset. Diagnosed with COVID19 and positive sorology for herpes zoster, without vesicular skin lesions. The first audiometry showed complete moderate-severe mixed hearing loss in the left ear, with a "U" curve. In the Brainstem Evoked Response Audiometry, it was not possible to record electrophysiological potentials at the maximum intensity of the device, 99dBHL. Initially, oral corticosteroid therapy was prescribed for two months, with no improvement. Based on the main hypothesis of viral involvement of the inner ear, directly or indirectly associated with COVID 19, valaciclovir was prescribed for seven days, without success. Finally, intratympanic infiltration was performed with five doses of 0.4-0.6mL dexamethasone, with considerable improvement. Conclusion: Early etiologic diagnosis of acute hearing loss is essential. Through this case, we show the promising treatment for deafness associated with COVID 19, with intratympanic corticosteroid infiltration. The results are the improvement in audiometric standards and especially in the quality of life of patients. [ABSTRACT FROM AUTHOR] |
